Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Neuromodulation and fMRI in Neurodegenerative Diseases Study

NCT: NCT06873750 · NOT_YET_RECRUITING

NCT IDNCT06873750
StatusNOT_YET_RECRUITING
Start Date2026-06-01
Completion2028-12-01

Brief Summary

In addition to neuronal loss, dysfunction in brain network connectivity has been identified as a correlate of cognitive deficits in neurodegenerative and post-traumatic brain injury states. Transcranial alternating current stimulation (tACS) has been suggested as a promising, non-invasive, method of normalizing network connectivity and hence improving cognition, notably memory. This study will examine the efficacy of tACS at improving working memory performance in patients with neurodegeneration and its correlation to changes in network connectivity, based on functional magnetic resonance imaging (fMRI) and electroencephalography (EEG) imaging data.

Frequently Asked Questions

What is Neuromodulation and fMRI in Neurodegenerative Diseases Study?

Neuromodulation and fMRI in Neurodegenerative Diseases Study is a clinical trial registered under NCT06873750. Current status: NOT_YET_RECRUITING.

What is the status of NCT06873750?

The current status of NCT06873750 (Neuromodulation and fMRI in Neurodegenerative Diseases Study) is: NOT_YET_RECRUITING.

When did Neuromodulation and fMRI in Neurodegenerative Diseases Study start?

Neuromodulation and fMRI in Neurodegenerative Diseases Study started on 2026-06-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.